TLR7 and neoplasm: In a preclinical mouse model, BDC-1001 an ISAC comprising a dual TLR7/8 agonist conjugated to HER2-targeted antibodies elicited a localized immune response resulting in tumor reduction of myeloid and T cells and immunological memory [60].